Erythropoietin‐induced pure red cell aplasia

Abstract

Erythropoietin-induced antibody-mediated PRCA is a well-known but rare complication of erythropoiesis-stimulating agent (ESA) therapy. The demonstration of absence or near absence of erythroblasts in bone marrow is crucial for its diagnosis. Other characteristics include reticulocytopenia, resistance to ESA therapy, and presence of anti-erythropoietin neutralizing antibodies. Management includes the cessation of ESA and the use of immunosuppressive treatment. I wish to express my greatest gratitude to Dr. Kate Leung for her guidance and supervision.